| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Stroke | 100 | 2022 | 2163 | 6.070 |
Why?
|
| Brain Ischemia | 48 | 2020 | 665 | 4.910 |
Why?
|
| Emergency Medical Services | 25 | 2022 | 225 | 3.390 |
Why?
|
| Tissue Plasminogen Activator | 35 | 2018 | 296 | 2.750 |
Why?
|
| Fibrinolytic Agents | 29 | 2018 | 377 | 2.370 |
Why?
|
| Thrombolytic Therapy | 17 | 2017 | 233 | 1.580 |
Why?
|
| Endovascular Procedures | 16 | 2018 | 366 | 1.450 |
Why?
|
| Cerebral Hemorrhage | 15 | 2019 | 198 | 1.450 |
Why?
|
| Thrombectomy | 10 | 2020 | 238 | 1.310 |
Why?
|
| American Heart Association | 15 | 2021 | 142 | 1.290 |
Why?
|
| Cardiopulmonary Resuscitation | 5 | 2018 | 72 | 1.180 |
Why?
|
| Emergency Service, Hospital | 9 | 2020 | 711 | 0.910 |
Why?
|
| Humans | 143 | 2022 | 68618 | 0.900 |
Why?
|
| Emergency Treatment | 3 | 2015 | 52 | 0.860 |
Why?
|
| Acute Coronary Syndrome | 3 | 2021 | 195 | 0.830 |
Why?
|
| Manikins | 1 | 2022 | 42 | 0.830 |
Why?
|
| Cerebral Angiography | 7 | 2019 | 151 | 0.730 |
Why?
|
| Computed Tomography Angiography | 2 | 2021 | 424 | 0.710 |
Why?
|
| Practice Guidelines as Topic | 10 | 2021 | 772 | 0.710 |
Why?
|
| Certification | 3 | 2020 | 66 | 0.700 |
Why?
|
| Urban Population | 2 | 2021 | 255 | 0.690 |
Why?
|
| Brain Edema | 1 | 2019 | 50 | 0.670 |
Why?
|
| Aged | 53 | 2019 | 14862 | 0.660 |
Why?
|
| Infarction, Middle Cerebral Artery | 2 | 2019 | 105 | 0.660 |
Why?
|
| Organizational Policy | 1 | 2019 | 42 | 0.660 |
Why?
|
| Early Diagnosis | 1 | 2019 | 122 | 0.660 |
Why?
|
| Intracranial Hypertension | 1 | 2019 | 53 | 0.650 |
Why?
|
| United States | 35 | 2021 | 7367 | 0.640 |
Why?
|
| Defibrillators | 1 | 2018 | 11 | 0.630 |
Why?
|
| Disease Management | 5 | 2021 | 248 | 0.620 |
Why?
|
| Rural Population | 2 | 2021 | 398 | 0.620 |
Why?
|
| Intracranial Hemorrhages | 2 | 2015 | 80 | 0.610 |
Why?
|
| Physicians | 3 | 2018 | 324 | 0.610 |
Why?
|
| Middle Aged | 54 | 2019 | 21147 | 0.580 |
Why?
|
| Neurology | 2 | 2015 | 43 | 0.570 |
Why?
|
| Patient Selection | 6 | 2012 | 592 | 0.570 |
Why?
|
| Tomography, X-Ray Computed | 13 | 2021 | 2324 | 0.540 |
Why?
|
| Cerebral Revascularization | 2 | 2014 | 45 | 0.540 |
Why?
|
| Female | 69 | 2020 | 38074 | 0.530 |
Why?
|
| Male | 69 | 2020 | 37321 | 0.530 |
Why?
|
| Life Support Care | 1 | 2015 | 12 | 0.530 |
Why?
|
| Time Factors | 26 | 2018 | 4655 | 0.530 |
Why?
|
| Acute Disease | 14 | 2019 | 658 | 0.500 |
Why?
|
| Health Knowledge, Attitudes, Practice | 4 | 2021 | 767 | 0.490 |
Why?
|
| Data Interpretation, Statistical | 6 | 2014 | 329 | 0.490 |
Why?
|
| Guideline Adherence | 3 | 2017 | 287 | 0.480 |
Why?
|
| Hospitals | 3 | 2022 | 265 | 0.480 |
Why?
|
| Time-to-Treatment | 5 | 2022 | 117 | 0.470 |
Why?
|
| Ischemic Attack, Transient | 5 | 2008 | 167 | 0.470 |
Why?
|
| Magnetic Resonance Angiography | 2 | 2012 | 181 | 0.460 |
Why?
|
| Treatment Outcome | 28 | 2020 | 7029 | 0.450 |
Why?
|
| Primary Health Care | 2 | 2021 | 703 | 0.440 |
Why?
|
| Cardiology | 2 | 2010 | 140 | 0.420 |
Why?
|
| Blood Pressure | 4 | 2015 | 1451 | 0.410 |
Why?
|
| Surgery, Computer-Assisted | 1 | 2012 | 52 | 0.410 |
Why?
|
| Societies, Medical | 4 | 2019 | 403 | 0.370 |
Why?
|
| Feasibility Studies | 3 | 2022 | 652 | 0.360 |
Why?
|
| Delivery of Health Care | 4 | 2021 | 445 | 0.360 |
Why?
|
| S100 Proteins | 2 | 2008 | 42 | 0.350 |
Why?
|
| Nerve Growth Factors | 2 | 2008 | 75 | 0.350 |
Why?
|
| Severity of Illness Index | 10 | 2018 | 1851 | 0.340 |
Why?
|
| Quality Improvement | 2 | 2017 | 413 | 0.340 |
Why?
|
| Adult | 33 | 2021 | 21403 | 0.320 |
Why?
|
| Reperfusion | 3 | 2014 | 78 | 0.320 |
Why?
|
| South Carolina | 6 | 2022 | 2752 | 0.310 |
Why?
|
| Recombinant Proteins | 7 | 2019 | 742 | 0.310 |
Why?
|
| Hematoma | 2 | 2006 | 47 | 0.310 |
Why?
|
| Recovery of Function | 5 | 2017 | 506 | 0.300 |
Why?
|
| Electrocardiography | 2 | 2008 | 601 | 0.290 |
Why?
|
| Subarachnoid Hemorrhage | 4 | 2019 | 61 | 0.280 |
Why?
|
| Ischemia | 2 | 2018 | 229 | 0.280 |
Why?
|
| Thrombomodulin | 1 | 2006 | 3 | 0.280 |
Why?
|
| Retrospective Studies | 14 | 2018 | 7277 | 0.280 |
Why?
|
| Myelin Basic Protein | 1 | 2006 | 62 | 0.270 |
Why?
|
| Emergency Medicine | 2 | 2005 | 88 | 0.270 |
Why?
|
| Phosphopyruvate Hydratase | 1 | 2006 | 35 | 0.270 |
Why?
|
| Hypertension | 9 | 2014 | 1535 | 0.270 |
Why?
|
| Hospitalization | 6 | 2019 | 978 | 0.270 |
Why?
|
| Gene Expression Profiling | 8 | 2014 | 498 | 0.260 |
Why?
|
| Aged, 80 and over | 23 | 2019 | 4848 | 0.260 |
Why?
|
| Triage | 3 | 2020 | 109 | 0.250 |
Why?
|
| Myocardial Ischemia | 1 | 2006 | 172 | 0.250 |
Why?
|
| Critical Care | 3 | 2022 | 263 | 0.250 |
Why?
|
| Risk Factors | 22 | 2019 | 5731 | 0.250 |
Why?
|
| Consensus | 2 | 2021 | 211 | 0.240 |
Why?
|
| Neuroprotective Agents | 2 | 2004 | 317 | 0.240 |
Why?
|
| Biomedical Research | 5 | 2019 | 310 | 0.240 |
Why?
|
| Logistic Models | 9 | 2013 | 1420 | 0.240 |
Why?
|
| Cerebrovascular Disorders | 4 | 2005 | 182 | 0.230 |
Why?
|
| Free Radical Scavengers | 1 | 2004 | 112 | 0.230 |
Why?
|
| Central Nervous System | 1 | 2004 | 107 | 0.230 |
Why?
|
| Hemodynamics | 1 | 2006 | 705 | 0.220 |
Why?
|
| Clinical Trials as Topic | 3 | 2014 | 848 | 0.220 |
Why?
|
| Advisory Committees | 3 | 2014 | 73 | 0.220 |
Why?
|
| Randomized Controlled Trials as Topic | 7 | 2015 | 931 | 0.210 |
Why?
|
| Airway Management | 1 | 2022 | 20 | 0.210 |
Why?
|
| Patient Acceptance of Health Care | 3 | 2019 | 468 | 0.210 |
Why?
|
| Sex Characteristics | 3 | 2014 | 295 | 0.210 |
Why?
|
| Adolescent | 16 | 2018 | 8912 | 0.210 |
Why?
|
| Perfusion | 2 | 2012 | 131 | 0.210 |
Why?
|
| Glasgow Coma Scale | 4 | 2019 | 65 | 0.200 |
Why?
|
| Biomarkers | 9 | 2014 | 1593 | 0.200 |
Why?
|
| Primary Prevention | 2 | 2014 | 115 | 0.200 |
Why?
|
| ST Elevation Myocardial Infarction | 1 | 2021 | 10 | 0.200 |
Why?
|
| Prospective Studies | 11 | 2017 | 3705 | 0.200 |
Why?
|
| Health Care Surveys | 3 | 2018 | 239 | 0.190 |
Why?
|
| Ambulances | 2 | 2019 | 27 | 0.190 |
Why?
|
| Gene Expression Regulation | 3 | 2014 | 1293 | 0.190 |
Why?
|
| Emergency Medical Technicians | 3 | 2007 | 14 | 0.190 |
Why?
|
| Atrial Fibrillation | 3 | 2015 | 249 | 0.190 |
Why?
|
| Infusions, Intravenous | 8 | 2017 | 334 | 0.180 |
Why?
|
| Survival Analysis | 2 | 2018 | 714 | 0.180 |
Why?
|
| Telemedicine | 4 | 2016 | 700 | 0.180 |
Why?
|
| Emergency Medical Service Communication Systems | 2 | 2012 | 25 | 0.180 |
Why?
|
| Factor VIIa | 1 | 2019 | 25 | 0.170 |
Why?
|
| Patient Transfer | 3 | 2021 | 86 | 0.170 |
Why?
|
| Early Medical Intervention | 2 | 2016 | 16 | 0.170 |
Why?
|
| Common Data Elements | 1 | 2019 | 4 | 0.170 |
Why?
|
| Young Adult | 9 | 2018 | 5717 | 0.170 |
Why?
|
| Antihypertensive Agents | 3 | 2014 | 498 | 0.170 |
Why?
|
| Gene Expression | 2 | 2012 | 770 | 0.170 |
Why?
|
| Aneurysm, Ruptured | 1 | 2019 | 40 | 0.160 |
Why?
|
| Double-Blind Method | 5 | 2019 | 1738 | 0.160 |
Why?
|
| Quality of Health Care | 3 | 2011 | 322 | 0.160 |
Why?
|
| Brain | 4 | 2019 | 2176 | 0.160 |
Why?
|
| Aspirin | 2 | 2018 | 295 | 0.160 |
Why?
|
| Risk Assessment | 4 | 2021 | 2007 | 0.160 |
Why?
|
| Research | 2 | 2017 | 214 | 0.160 |
Why?
|
| Transportation of Patients | 3 | 2012 | 46 | 0.160 |
Why?
|
| Out-of-Hospital Cardiac Arrest | 1 | 2018 | 11 | 0.160 |
Why?
|
| Headache | 1 | 1998 | 68 | 0.160 |
Why?
|
| Emergency Nursing | 2 | 2007 | 9 | 0.150 |
Why?
|
| First Aid | 2 | 2007 | 8 | 0.150 |
Why?
|
| Brain Injuries | 3 | 2014 | 268 | 0.150 |
Why?
|
| Health Personnel | 2 | 2011 | 286 | 0.150 |
Why?
|
| Health Services Accessibility | 2 | 2016 | 581 | 0.150 |
Why?
|
| Heart Arrest | 2 | 2008 | 113 | 0.150 |
Why?
|
| Cost-Benefit Analysis | 3 | 2017 | 504 | 0.150 |
Why?
|
| Awareness | 1 | 1998 | 81 | 0.150 |
Why?
|
| Odds Ratio | 9 | 2019 | 880 | 0.150 |
Why?
|
| Risk Adjustment | 1 | 2017 | 49 | 0.150 |
Why?
|
| Research Design | 4 | 2014 | 729 | 0.150 |
Why?
|
| Medically Uninsured | 1 | 2018 | 99 | 0.140 |
Why?
|
| Health Care Costs | 2 | 2017 | 346 | 0.140 |
Why?
|
| Focal Infection, Dental | 1 | 1996 | 1 | 0.140 |
Why?
|
| Facial Muscles | 1 | 1996 | 11 | 0.140 |
Why?
|
| Neck Muscles | 1 | 1996 | 6 | 0.140 |
Why?
|
| Apolipoproteins E | 4 | 2005 | 92 | 0.140 |
Why?
|
| Fasciitis, Necrotizing | 1 | 1996 | 15 | 0.140 |
Why?
|
| National Institutes of Health (U.S.) | 3 | 2018 | 109 | 0.140 |
Why?
|
| Poverty | 1 | 2018 | 219 | 0.140 |
Why?
|
| Population Surveillance | 1 | 1998 | 285 | 0.140 |
Why?
|
| Ohio | 8 | 2009 | 64 | 0.130 |
Why?
|
| National Institute of Neurological Disorders and Stroke (U.S.) | 2 | 2019 | 20 | 0.130 |
Why?
|
| Disability Evaluation | 5 | 2020 | 298 | 0.130 |
Why?
|
| Oxidative Stress | 2 | 2014 | 718 | 0.130 |
Why?
|
| Algorithms | 4 | 2013 | 1196 | 0.130 |
Why?
|
| Health Education | 4 | 2021 | 279 | 0.130 |
Why?
|
| Meta-Analysis as Topic | 1 | 2015 | 57 | 0.130 |
Why?
|
| Surveys and Questionnaires | 3 | 2019 | 2800 | 0.130 |
Why?
|
| Models, Theoretical | 1 | 2018 | 384 | 0.130 |
Why?
|
| Hospital Units | 2 | 2012 | 21 | 0.120 |
Why?
|
| Community-Based Participatory Research | 1 | 2016 | 133 | 0.120 |
Why?
|
| Statistics as Topic | 1 | 2015 | 219 | 0.120 |
Why?
|
| Quality of Life | 2 | 2015 | 1515 | 0.120 |
Why?
|
| Nervous System Diseases | 2 | 2018 | 142 | 0.120 |
Why?
|
| Longitudinal Studies | 1 | 2018 | 1054 | 0.120 |
Why?
|
| Intracranial Embolism | 1 | 2014 | 25 | 0.120 |
Why?
|
| Health Promotion | 1 | 2018 | 407 | 0.120 |
Why?
|
| Peroxiredoxin VI | 1 | 2014 | 18 | 0.120 |
Why?
|
| Leukocytes | 1 | 2014 | 99 | 0.120 |
Why?
|
| Association | 1 | 2013 | 5 | 0.120 |
Why?
|
| Cooperative Behavior | 1 | 2015 | 235 | 0.120 |
Why?
|
| Education, Medical, Continuing | 1 | 2015 | 136 | 0.120 |
Why?
|
| Databases, Factual | 2 | 2017 | 622 | 0.110 |
Why?
|
| Trauma Centers | 1 | 2015 | 197 | 0.110 |
Why?
|
| Endothelial Cells | 2 | 2007 | 384 | 0.110 |
Why?
|
| Anesthesia, General | 1 | 2014 | 86 | 0.110 |
Why?
|
| Patient Admission | 2 | 2012 | 99 | 0.110 |
Why?
|
| Diagnosis, Differential | 5 | 2008 | 1140 | 0.110 |
Why?
|
| Racism | 1 | 2014 | 59 | 0.110 |
Why?
|
| Intensive Care Units | 1 | 2015 | 344 | 0.110 |
Why?
|
| Monocytes | 3 | 2014 | 210 | 0.110 |
Why?
|
| Patient Education as Topic | 3 | 2016 | 425 | 0.110 |
Why?
|
| Neutrophils | 3 | 2014 | 204 | 0.110 |
Why?
|
| Facility Design and Construction | 1 | 2012 | 16 | 0.110 |
Why?
|
| Patient Care Team | 2 | 2012 | 311 | 0.100 |
Why?
|
| Medication Systems, Hospital | 1 | 2012 | 19 | 0.100 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 5 | 2012 | 320 | 0.100 |
Why?
|
| Efficiency | 1 | 2012 | 49 | 0.100 |
Why?
|
| Chromosomes, Human, Y | 1 | 2012 | 13 | 0.100 |
Why?
|
| General Practitioners | 1 | 2012 | 10 | 0.100 |
Why?
|
| Child Development Disorders, Pervasive | 1 | 2012 | 26 | 0.100 |
Why?
|
| Comprehensive Health Care | 2 | 2021 | 26 | 0.100 |
Why?
|
| tau Proteins | 2 | 2002 | 61 | 0.100 |
Why?
|
| Embolism | 2 | 2010 | 45 | 0.100 |
Why?
|
| Chromosomes, Human, X | 1 | 2011 | 24 | 0.100 |
Why?
|
| Genetic Predisposition to Disease | 3 | 2005 | 786 | 0.100 |
Why?
|
| Perfusion Imaging | 1 | 2011 | 27 | 0.100 |
Why?
|
| Task Performance and Analysis | 1 | 2012 | 150 | 0.100 |
Why?
|
| Delivery of Health Care, Integrated | 1 | 2012 | 77 | 0.100 |
Why?
|
| Magnetic Resonance Imaging | 2 | 2012 | 2223 | 0.100 |
Why?
|
| Wounds and Injuries | 1 | 2015 | 334 | 0.100 |
Why?
|
| Case-Control Studies | 8 | 2012 | 1553 | 0.100 |
Why?
|
| Patient Discharge | 3 | 2020 | 294 | 0.100 |
Why?
|
| Health Planning Guidelines | 2 | 2011 | 23 | 0.100 |
Why?
|
| Neuroimaging | 1 | 2012 | 122 | 0.100 |
Why?
|
| Medication Adherence | 1 | 2014 | 335 | 0.100 |
Why?
|
| Healthcare Disparities | 1 | 2015 | 378 | 0.090 |
Why?
|
| Diagnostic Imaging | 1 | 2012 | 201 | 0.090 |
Why?
|
| Predictive Value of Tests | 6 | 2013 | 1465 | 0.090 |
Why?
|
| S100 Calcium Binding Protein beta Subunit | 2 | 2008 | 15 | 0.090 |
Why?
|
| Therapeutic Equipoise | 1 | 2010 | 3 | 0.090 |
Why?
|
| Carotid Arteries | 2 | 2008 | 110 | 0.090 |
Why?
|
| Intracranial Hemorrhage, Hypertensive | 2 | 2012 | 5 | 0.090 |
Why?
|
| Stents | 1 | 2014 | 657 | 0.090 |
Why?
|
| Industry | 1 | 2009 | 28 | 0.080 |
Why?
|
| RNA, Messenger | 1 | 2013 | 1664 | 0.080 |
Why?
|
| Incidence | 6 | 2014 | 1603 | 0.080 |
Why?
|
| Conflict of Interest | 1 | 2009 | 48 | 0.080 |
Why?
|
| Neurons | 2 | 2006 | 881 | 0.080 |
Why?
|
| Academic Medical Centers | 1 | 2011 | 281 | 0.080 |
Why?
|
| Urinalysis | 1 | 2008 | 27 | 0.080 |
Why?
|
| Drug Therapy, Combination | 3 | 2006 | 649 | 0.080 |
Why?
|
| Blood Cells | 1 | 2008 | 27 | 0.080 |
Why?
|
| Natriuretic Peptide, Brain | 1 | 2008 | 101 | 0.080 |
Why?
|
| Resuscitation | 1 | 2008 | 77 | 0.080 |
Why?
|
| Clinical Laboratory Techniques | 1 | 2008 | 60 | 0.080 |
Why?
|
| Administration, Intravenous | 2 | 2018 | 89 | 0.080 |
Why?
|
| Matrix Metalloproteinase 9 | 1 | 2008 | 160 | 0.080 |
Why?
|
| Interprofessional Relations | 1 | 2009 | 188 | 0.080 |
Why?
|
| Societies | 1 | 2007 | 15 | 0.070 |
Why?
|
| Critical Pathways | 1 | 2007 | 33 | 0.070 |
Why?
|
| Biomedical Technology | 1 | 2007 | 14 | 0.070 |
Why?
|
| Brain Damage, Chronic | 1 | 2006 | 25 | 0.070 |
Why?
|
| Mass Screening | 1 | 2012 | 843 | 0.070 |
Why?
|
| Sex Factors | 4 | 2017 | 1266 | 0.070 |
Why?
|
| Cerebral Arteries | 1 | 2006 | 50 | 0.070 |
Why?
|
| Ultrasonography | 1 | 2008 | 453 | 0.070 |
Why?
|
| Kentucky | 5 | 2005 | 13 | 0.070 |
Why?
|
| Brain Infarction | 1 | 2006 | 54 | 0.070 |
Why?
|
| Health Policy | 2 | 2021 | 221 | 0.070 |
Why?
|
| Disease Models, Animal | 3 | 2017 | 2550 | 0.070 |
Why?
|
| Neuroglia | 1 | 2006 | 136 | 0.070 |
Why?
|
| Atherosclerosis | 1 | 2008 | 204 | 0.070 |
Why?
|
| Social Class | 1 | 2006 | 127 | 0.070 |
Why?
|
| Postoperative Complications | 2 | 2012 | 1615 | 0.060 |
Why?
|
| Haplotypes | 1 | 2005 | 174 | 0.060 |
Why?
|
| Plasminogen Activators | 1 | 2005 | 19 | 0.060 |
Why?
|
| Mental Disorders | 1 | 2010 | 659 | 0.060 |
Why?
|
| Fee-for-Service Plans | 1 | 2005 | 24 | 0.060 |
Why?
|
| Computer Simulation | 3 | 2014 | 706 | 0.060 |
Why?
|
| Mechanical Thrombolysis | 2 | 2015 | 29 | 0.060 |
Why?
|
| Toothache | 1 | 2004 | 7 | 0.060 |
Why?
|
| Bilirubin | 1 | 2004 | 51 | 0.060 |
Why?
|
| Nitrogen Oxides | 1 | 2004 | 7 | 0.060 |
Why?
|
| Evidence-Based Medicine | 3 | 2014 | 438 | 0.060 |
Why?
|
| Benzenesulfonates | 1 | 2004 | 30 | 0.060 |
Why?
|
| Human Growth Hormone | 1 | 2004 | 20 | 0.060 |
Why?
|
| Prolactin | 1 | 2004 | 61 | 0.060 |
Why?
|
| Heart Diseases | 3 | 2014 | 276 | 0.060 |
Why?
|
| Injections, Intra-Arterial | 3 | 2014 | 30 | 0.060 |
Why?
|
| Interleukins | 1 | 2004 | 79 | 0.060 |
Why?
|
| Platelet Aggregation Inhibitors | 3 | 2012 | 373 | 0.060 |
Why?
|
| Hypothermia, Induced | 1 | 2004 | 93 | 0.060 |
Why?
|
| International Cooperation | 3 | 2008 | 88 | 0.060 |
Why?
|
| Hypercholesterolemia | 1 | 2004 | 86 | 0.060 |
Why?
|
| Fusobacterium necrophorum | 1 | 2003 | 1 | 0.060 |
Why?
|
| Fusobacterium Infections | 1 | 2003 | 2 | 0.060 |
Why?
|
| Pharyngitis | 1 | 2003 | 10 | 0.060 |
Why?
|
| Urban Health Services | 1 | 2003 | 24 | 0.060 |
Why?
|
| Thrombophlebitis | 1 | 2003 | 47 | 0.060 |
Why?
|
| Jugular Veins | 1 | 2003 | 37 | 0.050 |
Why?
|
| Education, Continuing | 1 | 2003 | 28 | 0.050 |
Why?
|
| Advanced Cardiac Life Support | 1 | 2003 | 22 | 0.050 |
Why?
|
| Injections, Intravenous | 3 | 2014 | 215 | 0.050 |
Why?
|
| Burns | 1 | 2004 | 83 | 0.050 |
Why?
|
| Combined Modality Therapy | 2 | 2017 | 951 | 0.050 |
Why?
|
| Fibrinolysis | 1 | 2002 | 55 | 0.050 |
Why?
|
| Hydrocortisone | 1 | 2004 | 291 | 0.050 |
Why?
|
| Syndrome | 3 | 2008 | 255 | 0.050 |
Why?
|
| Follow-Up Studies | 3 | 2015 | 3259 | 0.050 |
Why?
|
| Problem-Based Learning | 1 | 2003 | 72 | 0.050 |
Why?
|
| Inpatients | 2 | 2019 | 208 | 0.050 |
Why?
|
| Head Injuries, Closed | 1 | 2002 | 9 | 0.050 |
Why?
|
| Intracranial Pressure | 1 | 2002 | 58 | 0.050 |
Why?
|
| Anticoagulants | 3 | 2012 | 356 | 0.050 |
Why?
|
| Information Services | 1 | 2002 | 22 | 0.050 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2004 | 212 | 0.050 |
Why?
|
| Oxygen Inhalation Therapy | 1 | 2002 | 32 | 0.050 |
Why?
|
| Decision Trees | 1 | 2002 | 74 | 0.050 |
Why?
|
| Secondary Care Centers | 1 | 2021 | 2 | 0.050 |
Why?
|
| Canada | 2 | 2017 | 267 | 0.050 |
Why?
|
| Age Factors | 3 | 2017 | 1864 | 0.050 |
Why?
|
| Comorbidity | 3 | 2017 | 1426 | 0.050 |
Why?
|
| Clinical Decision-Making | 1 | 2021 | 109 | 0.050 |
Why?
|
| Apoptosis | 1 | 2007 | 1641 | 0.040 |
Why?
|
| Air Ambulances | 1 | 1999 | 4 | 0.040 |
Why?
|
| Edema | 1 | 2000 | 66 | 0.040 |
Why?
|
| Cytokines | 1 | 2004 | 866 | 0.040 |
Why?
|
| Multivariate Analysis | 3 | 2011 | 1046 | 0.040 |
Why?
|
| Internship and Residency | 1 | 2005 | 596 | 0.040 |
Why?
|
| National Library of Medicine (U.S.) | 1 | 2019 | 1 | 0.040 |
Why?
|
| Infusions, Intra-Arterial | 2 | 2010 | 27 | 0.040 |
Why?
|
| Apolipoprotein E4 | 3 | 2005 | 31 | 0.040 |
Why?
|
| Probability | 2 | 2012 | 245 | 0.040 |
Why?
|
| Animals | 5 | 2017 | 20881 | 0.040 |
Why?
|
| Internet | 1 | 2002 | 390 | 0.040 |
Why?
|
| Reproducibility of Results | 3 | 2012 | 2077 | 0.040 |
Why?
|
| Placebo Effect | 1 | 2018 | 20 | 0.040 |
Why?
|
| Inflammation | 3 | 2014 | 1030 | 0.040 |
Why?
|
| Prevalence | 2 | 2013 | 1619 | 0.040 |
Why?
|
| Medical History Taking | 1 | 1998 | 94 | 0.040 |
Why?
|
| Physical Examination | 1 | 1998 | 152 | 0.040 |
Why?
|
| Intracranial Aneurysm | 1 | 2019 | 87 | 0.040 |
Why?
|
| Administration, Oral | 1 | 2018 | 411 | 0.040 |
Why?
|
| Global Health | 2 | 2007 | 136 | 0.040 |
Why?
|
| Quality-Adjusted Life Years | 1 | 2017 | 106 | 0.040 |
Why?
|
| Periodontal Abscess | 1 | 1996 | 2 | 0.040 |
Why?
|
| Europe | 1 | 2017 | 196 | 0.040 |
Why?
|
| Pilot Projects | 3 | 2008 | 1342 | 0.040 |
Why?
|
| Health Resources | 1 | 2017 | 76 | 0.030 |
Why?
|
| Cost Savings | 1 | 2017 | 110 | 0.030 |
Why?
|
| Enterobacteriaceae Infections | 1 | 1996 | 25 | 0.030 |
Why?
|
| Candidiasis | 1 | 1996 | 39 | 0.030 |
Why?
|
| Bayes Theorem | 1 | 2018 | 307 | 0.030 |
Why?
|
| Australia | 1 | 2017 | 235 | 0.030 |
Why?
|
| Fatal Outcome | 1 | 1996 | 164 | 0.030 |
Why?
|
| Cohort Studies | 2 | 2015 | 2358 | 0.030 |
Why?
|
| Child, Preschool | 2 | 2014 | 3187 | 0.030 |
Why?
|
| Health Surveys | 1 | 1998 | 489 | 0.030 |
Why?
|
| North Carolina | 1 | 2016 | 224 | 0.030 |
Why?
|
| Health Literacy | 1 | 2016 | 63 | 0.030 |
Why?
|
| Quality Indicators, Health Care | 1 | 2017 | 136 | 0.030 |
Why?
|
| Reperfusion Injury | 2 | 2008 | 320 | 0.030 |
Why?
|
| Netherlands | 1 | 2015 | 68 | 0.030 |
Why?
|
| Embolectomy | 1 | 2015 | 5 | 0.030 |
Why?
|
| Focus Groups | 1 | 2016 | 247 | 0.030 |
Why?
|
| Medicare | 1 | 2017 | 319 | 0.030 |
Why?
|
| Staphylococcal Infections | 1 | 1996 | 156 | 0.030 |
Why?
|
| Qualitative Research | 1 | 2016 | 369 | 0.030 |
Why?
|
| Congresses as Topic | 1 | 2015 | 85 | 0.030 |
Why?
|
| Erythroblasts | 1 | 2014 | 4 | 0.030 |
Why?
|
| Megakaryocytes | 1 | 2014 | 18 | 0.030 |
Why?
|
| Disease Progression | 1 | 2018 | 1038 | 0.030 |
Why?
|
| International Classification of Diseases | 1 | 2014 | 85 | 0.030 |
Why?
|
| Tomography Scanners, X-Ray Computed | 1 | 2014 | 32 | 0.030 |
Why?
|
| Hospitals, University | 2 | 2007 | 169 | 0.030 |
Why?
|
| Clinical Trials, Phase III as Topic | 1 | 2014 | 84 | 0.030 |
Why?
|
| Foundations | 1 | 2013 | 17 | 0.030 |
Why?
|
| Interviews as Topic | 1 | 2015 | 392 | 0.030 |
Why?
|
| Health Planning | 1 | 2013 | 23 | 0.030 |
Why?
|
| Risk | 2 | 2005 | 563 | 0.030 |
Why?
|
| Cardiovascular Diseases | 2 | 2012 | 940 | 0.030 |
Why?
|
| Gene Regulatory Networks | 1 | 2014 | 94 | 0.030 |
Why?
|
| Length of Stay | 1 | 2017 | 780 | 0.030 |
Why?
|
| Needs Assessment | 1 | 2015 | 186 | 0.030 |
Why?
|
| Costs and Cost Analysis | 1 | 2014 | 193 | 0.030 |
Why?
|
| Workflow | 1 | 2014 | 100 | 0.030 |
Why?
|
| Carotid Artery Diseases | 1 | 2014 | 83 | 0.030 |
Why?
|
| Sensitivity and Specificity | 2 | 2008 | 1753 | 0.030 |
Why?
|
| Numerical Analysis, Computer-Assisted | 1 | 2013 | 13 | 0.030 |
Why?
|
| Multicenter Studies as Topic | 1 | 2013 | 186 | 0.030 |
Why?
|
| Analysis of Variance | 1 | 2015 | 1040 | 0.030 |
Why?
|
| Alleles | 2 | 2005 | 386 | 0.030 |
Why?
|
| Thrombosis | 1 | 2014 | 218 | 0.030 |
Why?
|
| Apolipoprotein E2 | 2 | 2002 | 8 | 0.030 |
Why?
|
| Blood Coagulation Disorders | 1 | 2012 | 45 | 0.030 |
Why?
|
| Chronic Disease | 1 | 2017 | 1330 | 0.030 |
Why?
|
| Oxidation-Reduction | 1 | 2014 | 567 | 0.030 |
Why?
|
| Sex Distribution | 2 | 2004 | 274 | 0.030 |
Why?
|
| Risk Management | 1 | 2012 | 37 | 0.030 |
Why?
|
| Bone Plates | 1 | 1992 | 49 | 0.030 |
Why?
|
| Age Distribution | 2 | 2004 | 320 | 0.030 |
Why?
|
| Regional Blood Flow | 1 | 2012 | 168 | 0.030 |
Why?
|
| Secondary Prevention | 1 | 2013 | 291 | 0.030 |
Why?
|
| alpha-Galactosidase | 1 | 2011 | 3 | 0.030 |
Why?
|
| Risperidone | 1 | 2012 | 48 | 0.020 |
Why?
|
| Molecular Sequence Data | 1 | 2014 | 1447 | 0.020 |
Why?
|
| Cervical Vertebrae | 1 | 1992 | 86 | 0.020 |
Why?
|
| Genotype | 2 | 2005 | 786 | 0.020 |
Why?
|
| Stochastic Processes | 1 | 2011 | 27 | 0.020 |
Why?
|
| Community-Institutional Relations | 1 | 2012 | 59 | 0.020 |
Why?
|
| Spinal Fusion | 1 | 1992 | 90 | 0.020 |
Why?
|
| Bone Screws | 1 | 1992 | 90 | 0.020 |
Why?
|
| Neurosurgical Procedures | 1 | 2012 | 98 | 0.020 |
Why?
|
| Biostatistics | 1 | 2011 | 43 | 0.020 |
Why?
|
| Area Under Curve | 1 | 2011 | 238 | 0.020 |
Why?
|
| Disabled Persons | 1 | 2012 | 94 | 0.020 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 2 | 2002 | 507 | 0.020 |
Why?
|
| Hemorrhage | 2 | 2005 | 328 | 0.020 |
Why?
|
| Fibrin Tissue Adhesive | 1 | 1990 | 17 | 0.020 |
Why?
|
| RNA | 1 | 2011 | 171 | 0.020 |
Why?
|
| Dura Mater | 1 | 1990 | 23 | 0.020 |
Why?
|
| Bias | 1 | 2011 | 148 | 0.020 |
Why?
|
| Cerebrovascular Circulation | 1 | 2012 | 296 | 0.020 |
Why?
|
| Cholesterol | 1 | 2012 | 331 | 0.020 |
Why?
|
| Suture Techniques | 1 | 1990 | 75 | 0.020 |
Why?
|
| Emergencies | 1 | 2010 | 107 | 0.020 |
Why?
|
| Cross-Sectional Studies | 1 | 2017 | 2279 | 0.020 |
Why?
|
| Child | 2 | 2012 | 6405 | 0.020 |
Why?
|
| Transcription Factors | 1 | 2014 | 753 | 0.020 |
Why?
|
| Clinical Protocols | 2 | 2002 | 172 | 0.020 |
Why?
|
| Proportional Hazards Models | 1 | 2012 | 792 | 0.020 |
Why?
|
| Antipsychotic Agents | 1 | 2012 | 247 | 0.020 |
Why?
|
| Protein Processing, Post-Translational | 1 | 2011 | 284 | 0.020 |
Why?
|
| Genome-Wide Association Study | 1 | 2010 | 240 | 0.020 |
Why?
|
| Up-Regulation | 1 | 2011 | 682 | 0.020 |
Why?
|
| Brain Injury, Chronic | 1 | 2008 | 4 | 0.020 |
Why?
|
| Guidelines as Topic | 1 | 2009 | 123 | 0.020 |
Why?
|
| Prognosis | 2 | 2005 | 2093 | 0.020 |
Why?
|
| Caregivers | 1 | 2012 | 365 | 0.020 |
Why?
|
| Brain Diseases | 1 | 2008 | 78 | 0.020 |
Why?
|
| Models, Statistical | 1 | 2011 | 448 | 0.020 |
Why?
|
| Platelet Glycoprotein GPIb-IX Complex | 1 | 2007 | 7 | 0.020 |
Why?
|
| Platelet Endothelial Cell Adhesion Molecule-1 | 1 | 2007 | 29 | 0.020 |
Why?
|
| E-Selectin | 1 | 2007 | 44 | 0.020 |
Why?
|
| Cognition Disorders | 1 | 2010 | 342 | 0.020 |
Why?
|
| Education | 1 | 2007 | 83 | 0.020 |
Why?
|
| Virginia | 1 | 2007 | 45 | 0.020 |
Why?
|
| Hospitals, Community | 1 | 2007 | 64 | 0.020 |
Why?
|
| Blood Platelets | 1 | 2008 | 284 | 0.020 |
Why?
|
| Particle Size | 1 | 2007 | 201 | 0.020 |
Why?
|
| Statistics, Nonparametric | 1 | 2007 | 306 | 0.020 |
Why?
|
| Necrosis | 1 | 2007 | 239 | 0.020 |
Why?
|
| Medical Records | 1 | 2007 | 121 | 0.020 |
Why?
|
| Flow Cytometry | 1 | 2007 | 489 | 0.020 |
Why?
|
| Introns | 1 | 2005 | 68 | 0.020 |
Why?
|
| Linkage Disequilibrium | 1 | 2005 | 91 | 0.020 |
Why?
|
| Exons | 1 | 2005 | 122 | 0.020 |
Why?
|
| Infant | 1 | 2012 | 2891 | 0.020 |
Why?
|
| Alberta | 1 | 2005 | 15 | 0.020 |
Why?
|
| Spinal Puncture | 1 | 2004 | 38 | 0.020 |
Why?
|
| Pregnancy | 1 | 2010 | 2334 | 0.020 |
Why?
|
| Stroke Rehabilitation | 1 | 2009 | 335 | 0.020 |
Why?
|
| Sus scrofa | 1 | 2004 | 74 | 0.020 |
Why?
|
| Hospitals, Urban | 1 | 2004 | 46 | 0.020 |
Why?
|
| Health Services Misuse | 1 | 2004 | 15 | 0.020 |
Why?
|
| Referral and Consultation | 1 | 2007 | 383 | 0.010 |
Why?
|
| Body Surface Area | 1 | 2004 | 20 | 0.010 |
Why?
|
| Immunocompromised Host | 1 | 2004 | 55 | 0.010 |
Why?
|
| Polymorphism, Genetic | 1 | 2005 | 301 | 0.010 |
Why?
|
| Eligibility Determination | 1 | 2004 | 31 | 0.010 |
Why?
|
| Time and Motion Studies | 1 | 2003 | 16 | 0.010 |
Why?
|
| Clindamycin | 1 | 2003 | 25 | 0.010 |
Why?
|
| Injury Severity Score | 1 | 2004 | 204 | 0.010 |
Why?
|
| Metronidazole | 1 | 2003 | 28 | 0.010 |
Why?
|
| Midwestern United States | 1 | 2003 | 36 | 0.010 |
Why?
|
| Outpatients | 1 | 2004 | 127 | 0.010 |
Why?
|
| Smoking Cessation | 1 | 2012 | 1034 | 0.010 |
Why?
|
| Regression Analysis | 1 | 2005 | 737 | 0.010 |
Why?
|
| Mortality | 1 | 2004 | 163 | 0.010 |
Why?
|
| Peptides | 1 | 2006 | 455 | 0.010 |
Why?
|
| Apolipoprotein E3 | 1 | 2002 | 7 | 0.010 |
Why?
|
| Smoking | 2 | 2002 | 1452 | 0.010 |
Why?
|
| Chromatography, Thin Layer | 1 | 2002 | 52 | 0.010 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2005 | 627 | 0.010 |
Why?
|
| Mouth Mucosa | 1 | 2002 | 51 | 0.010 |
Why?
|
| Informed Consent | 1 | 2003 | 127 | 0.010 |
Why?
|
| Immunoblotting | 1 | 2002 | 254 | 0.010 |
Why?
|
| Health Services Research | 1 | 2003 | 209 | 0.010 |
Why?
|
| Brain Chemistry | 1 | 2002 | 173 | 0.010 |
Why?
|
| alpha 1-Antitrypsin | 1 | 2002 | 61 | 0.010 |
Why?
|
| Protein Isoforms | 1 | 2002 | 246 | 0.010 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2004 | 626 | 0.010 |
Why?
|
| Curriculum | 1 | 2005 | 575 | 0.010 |
Why?
|
| Teaching | 1 | 2003 | 169 | 0.010 |
Why?
|
| Demography | 1 | 2002 | 279 | 0.010 |
Why?
|
| Educational Status | 1 | 2002 | 273 | 0.010 |
Why?
|
| Educational Measurement | 1 | 2003 | 254 | 0.010 |
Why?
|
| Genetic Testing | 1 | 2002 | 159 | 0.010 |
Why?
|
| Program Evaluation | 1 | 2003 | 502 | 0.010 |
Why?
|
| Mutation | 1 | 2005 | 1213 | 0.010 |
Why?
|
| Motion Sickness | 1 | 1999 | 6 | 0.010 |
Why?
|
| Confusion | 1 | 1999 | 20 | 0.010 |
Why?
|
| Autopsy | 1 | 1999 | 56 | 0.010 |
Why?
|
| Decision Making | 1 | 2003 | 410 | 0.010 |
Why?
|
| Drug Administration Schedule | 1 | 2000 | 567 | 0.010 |
Why?
|
| Safety | 1 | 1999 | 145 | 0.010 |
Why?
|
| Analgesics, Opioid | 1 | 2004 | 498 | 0.010 |
Why?
|
| Time Management | 1 | 1999 | 12 | 0.010 |
Why?
|
| Body Mass Index | 1 | 2002 | 867 | 0.010 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2002 | 504 | 0.010 |
Why?
|
| Echocardiography | 1 | 1999 | 515 | 0.010 |
Why?
|
| Anti-Bacterial Agents | 1 | 2003 | 1026 | 0.010 |
Why?
|
| Alcohol Drinking | 1 | 2002 | 805 | 0.010 |
Why?
|
| Alcoholism | 1 | 2002 | 1109 | 0.010 |
Why?
|
| Biomechanical Phenomena | 1 | 1992 | 368 | 0.010 |
Why?
|
| Spine | 1 | 1990 | 46 | 0.010 |
Why?
|
| Dogs | 1 | 1990 | 490 | 0.010 |
Why?
|
| Wound Healing | 1 | 1990 | 260 | 0.000 |
Why?
|